{
  "company": {
    "name": "Alphyn Biologics",
    "website": "https://alphynbiologics.com/",
    "record": "https://startuphistory.org/c/alphynbiologics.com"
  },
  "status": null,
  "history_since": "2019-08-18T05:11:14.000Z",
  "baseline": {
    "snapshot_id": "3d940946bd8ce934867232dca112653e5e98c2974372cd3e94db5ad59c852612",
    "observed_at": "2020-08-11T13:15:36.000Z",
    "headline": "alphyn Biologics, LLC",
    "description": null,
    "evidence": "https://web.archive.org/web/20200811131536/https://alphynbiologics.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-04T11:20:23.790Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2022-07-04T14:21:03.000Z",
      "variants": [
        {
          "headline": "alphyn Biologics, LLC",
          "subhead": null,
          "observed_at": "2020-08-11T13:15:36.000Z",
          "evidence": "https://web.archive.org/web/20200811131536/https://alphynbiologics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Alphyn Biologics and AB-101",
          "subhead": null,
          "observed_at": "2021-07-25T05:06:41.000Z",
          "evidence": "https://web.archive.org/web/20210725050641/https://www.alphynbiologics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Alphyn Biologics and AB-101",
          "subhead": null,
          "observed_at": "2022-01-19T19:01:40.000Z",
          "evidence": "https://web.archive.org/web/20220119190140/https://www.alphynbiologics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Alphyn Biologics and AB-101",
          "subhead": "Alphyn Biologics is creating a new class of drugs, Multi-Target Therapeutics™, for more effective therapies to treat skin disease.",
          "observed_at": "2022-07-04T14:21:03.000Z",
          "evidence": "https://web.archive.org/web/20220704142103/https://alphynbiologics.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Alphyn Biologics and AB-101",
      "subhead": "Alphyn Biologics is creating a new class of drugs, Multi-Target Therapeutics™, for more effective therapies to treat skin disease.",
      "from": "2020-08-11T13:15:36.000Z",
      "to": "2022-07-04T14:21:03.000Z",
      "captures": 4,
      "evidence": "https://web.archive.org/web/20220704142103/https://alphynbiologics.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2020-08-11T13:15:36.000Z",
          "to": "2022-07-04T14:21:03.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-d18e85c3f9959af79a5e5f4ac9a6f623e18330e8b0effda634dde139a43bd9aa:f7d27a36490bd4907ee45b1de12cb2678f1568f46fe968b6e726dcea81d2bdb2:funding:893929f2c7633f5d",
      "before_evidence": "https://web.archive.org/web/20250701141451/https://alphynbiologics.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Alphyn News Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline December 12, 2025 Alphyn Expands P…”.",
      "between": {
        "from": "2025-07-01T14:14:51.000Z",
        "to": "2026-01-14T23:40:06.000Z"
      },
      "evidence": "https://web.archive.org/web/20260114234006/https://alphynbiologics.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Alphyn Biologics” company record, https://startuphistory.org/c/alphynbiologics.com"
}